Executive Summary

Clinical stage immuno-oncology company with 2 broadly applicable platform technologies

        • CAR-CIK platform (allogeneic cytokine-induced killer (CIK) cells derived from healthy donor PBMCs)
        • Autologous RNA loaded dendritic cell platform

Experienced management team with key members having worked together in the field of cell therapy for 19+ years

Fully integrated biotechnology company

    • Operates a 20K Sq. Ft. GMP manufacturing facility with 11 clean rooms in Durham, NC
    • In-house R&D and process development

Strong clinical efficacy/safety data from completed clinical trials with multiple trials on-going across several indications

Groundbreaking collaboration with Memorial Sloan Kettering extending CAR-CIK platform to solid tumors

    • Combines cōIMMUNE® technology with proprietary CAR technologies

    • Working closely with several world-class laboratories at MSK